Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

OVID Relative to the S&P 500

OVID Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Ovid Therapeutics Inc. (NASD:OVID) seasonal charts above shows that a Buy Date of March 13 and a Sell Date of June 11 has resulted in a geometric average return of 6.38% above the benchmark rate of the S&P 500 Total Return Index over the past 7 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 7 years by an average of 43.29% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 7 years of data is available for shares of OVID, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class?drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

To download OVID seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: OVID